These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10892137)

  • 21. Hematopoietic growth factors--not whether, but when and where.
    Hoelzer D
    N Engl J Med; 1997 Jun; 336(25):1822-4. PubMed ID: 9187075
    [No Abstract]   [Full Text] [Related]  

  • 22. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Granulocyte transfusions. Return to the past].
    Muncunill J
    Med Clin (Barc); 1999 May; 112(15):574-6. PubMed ID: 10365384
    [No Abstract]   [Full Text] [Related]  

  • 24. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
    Adams JR; Angelotta C; Bennett CL
    J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
    [No Abstract]   [Full Text] [Related]  

  • 25. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
    Wingard JR; Elmongy M
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Granulocyte colony-stimulating factors: finding the right indication.
    Lyman GH; Shayne M
    Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
    Jørgensen HG; Copland M; Holyoake TL
    Cancer; 2005 Jan; 103(1):210-11. PubMed ID: 15540243
    [No Abstract]   [Full Text] [Related]  

  • 28. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical use of granulocyte colony-stimulating factor in infectious diseases.
    Gaviria JM; Garrido SM; Root RK
    Curr Clin Top Infect Dis; 2001; 21():302-22. PubMed ID: 11572156
    [No Abstract]   [Full Text] [Related]  

  • 31. Granulocyte transfusion therapy for treatment of infections after cytotoxic chemotherapy.
    Hübel K; Engert A
    Onkologie; 2003 Feb; 26(1):73-9. PubMed ID: 12624522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Granulocyte colony-stimulating factor in the treatment of neutropenia associated with HIV infection].
    Moreno García M; Fernández González F; Fernández Rodríguez E; Portús de Marco MV
    Med Clin (Barc); 1996 Jul; 107(6):237-8. PubMed ID: 8755453
    [No Abstract]   [Full Text] [Related]  

  • 33. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of granulocyte colony-stimulating factor for patients with recent myocardial infarction: a meta-analysis.
    Fan L; Chen L; Fu F; Lin C
    Int J Cardiol; 2008 Oct; 129(3):455-7. PubMed ID: 17706304
    [No Abstract]   [Full Text] [Related]  

  • 35. Acting on imperfect evidence: How much regret are we ready to accept?
    Djulbegovic B; Frohlich A; Bennett CL
    J Clin Oncol; 2005 Oct; 23(28):6822-5. PubMed ID: 16145058
    [No Abstract]   [Full Text] [Related]  

  • 36. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of granulocyte colony-stimulating factor (G-CSF) on the activity of granulocyte enzymes in children with cancer who developed neutropenia after chemotherapy.
    Czygier M; Dakowicz L; Szmitkowski M
    Adv Med Sci; 2008; 53(2):278-82. PubMed ID: 18614436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Questions on oncology].
    Misset JL
    Presse Med; 1998 Jul 4-11; 27(24):1209-10. PubMed ID: 9767773
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.